You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》花旗升信達生物(01801.HK)目標價至110元 上調每股盈測
阿思達克 08-28 14:26
花旗發表研究報告指,信達生物(01801.HK)上半年收入按年增51%至60億元人民幣,當中產品銷售額按年增37%;期內虧轉盈賺8.34億元元人民幣,而去年同期錄淨虧損3.93億元人民幣。另外,集團旗下藥物IBI363用於IO治療sqNSCLC的全球第三階段研究即將啟動,下半年亦有多款新藥數據披露。 該行認為,信達生物已進入一個新篇章,在創新的浪潮下,本地銷售穩健。該行將集團目標價由105元上調至110元,維持「買入」評級,並將其2025至2027年收入預測上調8%、3%及2%,基於強勁的增長動能,並將每股盈利預測由原預期的0.04、0.48及1.19元人民幣,上調至0.46、0.58及1.26元人民幣。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account